The hurdle of patents validity in price fixing of takeover is better and AZN got its prime demand met.
Now they are negotiating in good faith. It will be over $13.00 when agreed.
it seems that joe want's consideration for the long term reduce it trial as well as statin combo..vascepa is not just a better replacement for loveza...bp will not get this for loveza numbers and we are lucky that joe isn't just flipping it for 15...3 or 4 guys would love to have vascepa and one will take the plunge sooner than later...
Sophisticated BP will be able to understand the value or lack of it from NCE and be able to #$%$ the market for Vascepa independent of the early sales numbers. The early numbers will represent a combinatin of the merits of the product but also the effort/marketing that has taken place. Even if there is a slow start BP will presume that their capabilities could ramp things up significantly. They also know waiting may increase the price. Given how far down the shorts have been able to drive this, now would be a good time to strike if you had confidence in the product - and I think they do.
JZ would never go for 13. Remember Lovaza made over a billion last year now we have a product that works better, safer and will be available for larger population once Anchor is approved. Try 17-19 if not a bit higher.